2010
Surrogate endpoints in randomized cardiovascular clinical trials
Domanski M, Pocock S, Bernaud C, Borer J, Geller N, Revkin J, Zannad F. Surrogate endpoints in randomized cardiovascular clinical trials. Fundamental & Clinical Pharmacology 2010, 25: 411-413. PMID: 20698890, DOI: 10.1111/j.1472-8206.2010.00865.x.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkersCardiovascular DiseasesEndpoint DeterminationHumansRandomized Controlled Trials as TopicReproducibility of Results
2007
Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future
Revkin JH, Shear CL, Pouleur HG, Ryder SW, Orloff DG. Biomarkers in the Prevention and Treatment of Atherosclerosis: Need, Validation, and Future. Pharmacological Reviews 2007, 59: 40-53. PMID: 17329547, DOI: 10.1124/pr.59.1.1.Peer-Reviewed Original ResearchMeSH KeywordsAtherosclerosisBiomarkersCardiovascular AgentsCarotid ArteriesCoronary AngiographyForecastingHumansReproducibility of ResultsTreatment OutcomeUltrasonographyConceptsAtherosclerotic progressionClinical trialsCardiovascular diseaseCardiovascular outcomesSurrogate markerCarotid intima-media thicknessIdeal surrogate markerFuture cardiovascular eventsIntima-media thicknessCause of morbidityNew cardiovascular drugsQuantitative coronary angiographyTreatment of atherosclerosisNovel therapeutic strategiesB-mode ultrasoundAtheroma volumeCardiovascular eventsCardiovascular riskCoronary angiographyEffective therapySurrogate endpointsCardiovascular drugsTherapeutic strategiesIntravascular ultrasoundSuch trials